LA JOLLA, Calif., Nov. 11 /PRNewswire/ -- SIBIA Neurosciences, Inc.,
(Nasdaq: SIBI) today announced that Stephen F. Keane has been named Vice
President, Corporate Development.
    Mr. Keane brings to SIBIA more than 13 years of experience in the medical
and biotechnology areas.  Prior to joining SIBIA, Mr. Keane was Director,
Business Development at Molecular Biosystems, Inc. in San Diego, where he was
responsible for negotiating corporate partnerships.  He previously served as
Director, Investor Relations at Molecular Biosystems, Inc.  Prior to Molecular
Biosystems, he was Senior Account Executive-Bioscience Division with Stoorza,
Ziegus & Metzger, responsible for all aspects of corporate communications
programs for biotechnology and healthcare clients.  Previous to that,
Mr. Keane held a position at UCSD Medical Center as Scientific Editor,
Radiology Department.  Mr. Keane holds a B.A. from San Diego State University.
    "We are excited to add Stephen Keane to our management team.  His broad
biotechnology and healthcare background including licensing, financings,
strategic planning and corporate communications, will be highly beneficial in
assisting SIBIA to achieve its strategic goals," said William T. Comer, Ph.D.,
SIBIA's President and Chief Executive Officer.
    SIBIA Neurosciences, Inc. is engaged in the discovery and development of
novel small molecule therapeutics for the treatment of neurodegenerative,
neuropsychiatric and neurological disorders, many of which have large patient
populations and represent critical unmet medical needs.  SIBIA is a leader in
the development of proprietary drug discovery platforms that combine key tools
necessary for modern drug discovery, including genomics, high throughput
screening, advanced combinatorial chemistry techniques and pharmacology.  The
Company's proprietary molecular targets and drug candidates, together with its
drug discovery technologies and research expertise, have enabled the Company
to establish several corporate collaborations, which currently include
Bristol-Myers Squibb Company and Meiji Seika Kaisha, Ltd., and multiple
technology licensing arrangements.

    This press release contains forward-looking statements that involve risks
and uncertainties.  As a result, actual results could differ materially from
those discussed herein.  These risks and uncertainties include SIBIA's
reliance on corporate partnerships and ability to enter into new corporate
partnerships, whether SIBIA will be successful in demonstrating the safety and
efficacy of SIB-1508Y and SIB-1553A in humans, whether SIBIA will be able to
meet its development goals with respect to its drug candidates and proprietary
targets, SIBIA's early stage of development, the new and uncertain state of
SIBIA's technologies, SIBIA's future capital needs and the uncertainty of
receiving additional funding, uncertainties regarding patents, proprietary
rights and regulatory matters, and other research, development and market
risks.  These and other risks and uncertainties are more fully set forth in
SIBIA's most recently filed Forms 10-Q and 10-K.

Link to this page: